Biomaterial is an abbreviated form of the term biocompatible material, which can be defined as â€œa synthetic or natural material used to replace part of a living system or to function in intimate contact with living tissueâ€. Biomaterials are intended to interface with biological systems; they may be viable or non-viable. Artificial hips, vascular stents, artificial pacemakers and catheters are all made from different biomaterials.
The category of biomaterials now generally includes biomimetic materials â€“ synthetic constructs with compositions and properties similar to biological materials. Calcium hydroxyapatite, used as a coating on artificial hips, is a typical example; it is used as a bone replacement and facilitates attachment of an implant to living bone. The term â€œorthopaedic biomaterialsâ€ applies, clearly, to biomaterials used to replace, augment, heal or otherwise enhance the function of bone which is damaged or deficient as a result of disease or trauma.
The orthopaedic biomaterials field is like a cake that can be cut in various ways; for example by the types of materials used, the different structures involved, and by the clinical uses to which they are put. And of course the business of orthopaedic biomaterials can involve analysis of the market (actual and potential) and of the industry which supplies these materials and the devices of which they are made. Â Segmentation of the orthopedic biomaterials market can be made as follows:
- Other Orthopedic Biomaterials
- Growth Factors
- Surgical Sealants and Glues
- Tissue Engineering
Below is the geographic segmentation of the worldwide market for orthopedic biomaterials (drawn from Report #M625):
The current valuation of the orthopaedic biomaterials segment is around $5 billion, representing over 17% of the orthopaedic total. It is also estimated that this market segment will grow at over 13% per year, which is more than double the rate for the overall orthopaedics market. At this rate the biomaterials segment will achieve a value of $9.4 billion by 2011 and will represent 28% of all orthopaedic product sales.
Drawn from “Emerging Trends, Technologies and Opportunities in the Markets for Orthopedic Biomaterials, Worldwide,” report #M625. This report may be purchased online or via Google Checkout, below.Â